The use of thiotepa (TH) is increasing, especially in stem cell transplantation, mainly due to its safety and bloodbrain barrier penetration. We evaluated the use of TH in a murine model simulating autologous stem cell transplantation, with or without additional agents. Between 1 and 11 days following inoculation of BALB/c mice with 10 5 -10 8 B-cell leukemia (BCL1) cells (simulating pre-transplant leukemia loads), each group received an 'inductionlike' irradiation and/or cytotoxic regimen. Animals were either followed without treatment, or an adoptive transfer (AT) was performed to untreated BALB/c mice. Administered alone without AT, high-dose TH did not change the time to appearance of leukemia. Nevertheless, in the AT experiments, TH as a single agent showed better antileukemic activity than busulfan (BU). Cyclophosphamide (CY)-containing regimens were the most effective, and the TH-CY combination was as effective as the commonly used BU-CY combination, and more effective than the BU-TH combination. Moreover, a synergistic effect was seen in the TH-CY combination (none of the animals developed leukemia, whereas 4/10 animals in the CY-TBI group developed leukemia (P ¼ 0.029)). In conclusion, although TH produced only a moderate effect against BCL1 leukemia when used alone, its combination with CY is promising and should be tested further in allogeneic murine models and clinical studies.
Introduction
Thiotepa (TH, triethylene thiophosphoramide), an ethylene amide, developed by Lederle Laboratories in 1952, possesses mechlorethamine-like alkylating activity and has been used clinically for over 35 years. 1 It is of particular use in breast cancer, mainly as second-line treatment. 2 TH has been given intrathecally for carcinomatous meningitis, and intravesically for bladder carcinoma. 3, 4 Mild-to-moderate activity was observed in several solid tumors and hematological malignancies. 1, 5 There has been, however, a sustained interest in defining clinical roles for TH.
In recent years, the use of the drug has been increasing in view of the possibility to increase its dose significantly (by a factor of 10-22, in contrast with only a 3-to 5-fold increase in most of the other antitumor agents), accompanied with rescue by re-infusion of cryopreserved autologous bone marrow or peripheral stem cells. [6] [7] [8] [9] Thus, TH has become one of the most useful drugs in bone marrow transplantation protocols. Yet no studies compared the efficacy of high-dose TH in combination with other chemotherapeutic agents.
Spontaneous murine B-cell leukemia of BALB/c mice 10 provides a high-quality experimental model for studying the effect of chemotherapy, with or without radiotherapy, on a B-lymphoid neoplasm resembling human disease.
Our goal in the present series of experiments using the described murine leukemia model was to evaluate the efficacy of various doses of TH, and determine its role in combination with other drugs.
Materials and methods

Animals
Two-to 4-month-old inbred male and female BALB/c mice were purchased from the Hebrew University School of Medicine (Jerusalem, Israel) for use as leukemia recipients. Mice were kept under clean (SPF) conditions with autoclaved cages and sawdust. Food and acidified water were supplied as required.
Total-body irradiation
Recipient mice were placed in irradiation chambers on day À1 and exposed to a myeloablative dose of total-body irradiation (TBI) with 200 cGy given twice daily on 3 consecutive days at 56 cGy min À1 (900 cGy is lethal in this model if no additional spleen or marrow stem cells are administered; data not shown). TBI was delivered by a Philips X-ray unit (250 kV, 20 mA) (Varian Oncology Systems, Zug, Switzerland) with a 0.2-mm Cu filter. Source to skin distance was 70 cm.
Chemotherapy
The chemotherapeutic agents used in this study included TH, cyclophosphamide, busulfan (BU), melphalan, cytosine arabinoside, carmustine (BiCNu) or etoposide. The dose chosen for each agent was calculated on a per kilogram basis to yield doses comparable to, or higher than those used in clinical practice, particularly in BMT protocols (Table 1 ). All chemotherapeutic agents and TBI were administered on the same days.
Murine B-cell leukemia B-cell leukemia/lymphoma (BCL1) was maintained in vivo in BALB/c mice by intravenous passage of 10 6 -10 7 peripheral blood lymphocytes obtained from tumor-bearing mice. It has been shown previously that even a small inoculum of BCL1 might be sufficient to cause typical leukemia in all recipients.
11 All recipients of 410-100 BCL1 cells develop splenomegaly and marked lymphocytosis in the blood. Weekly peripheral blood lymphocyte counts were carried out in all experimental animals.
Preparation of spleen cells for inoculation of BCL1 lymphoma/leukemia and for adoptive transfer Spleens were removed aseptically from BALB/c mice following leukemic inoculation and antileukemic treatment, then teased through a nylon mesh into RPMI 1640 medium (Life Technologies, Grand Island, NY, USA) to create a single-cell suspension that was injected into the lateral tail vein of each recipient.
Adoptive transfer experiments assessing efficacy of the induction treatment on BCL1 To investigate minimal residual disease and to exclude early toxic deaths, spleen cells from the treated mice were transferred to normal BALB/c mice at a constant timing. The purpose of variability in the timing of adoptive transfer (AT) in the different experiments is to differentiate between disease stages that range from minimal residual disease (in which longer time to AT is needed to identify postinduction residual disease) to high disease load (where a shorter time is needed). Untreated BALB/c mice receiving 10 5 spleen cells obtained from each experimental group were used to determine whether or not at the time of AT, clonogenic BCL1 were still present in the spleen of treated mice. Recipients were observed for the development of leukemia. Splenomegaly and peripheral blood lymphocyte counts were monitored to confirm the presence of leukemia, and to determine whether leukemia was indeed the cause of death.
Statistical analysis
Significance was determined using the Student's t-test and Kaplan-Meier survival analysis (medcalc, Belgium); Pp0.05 was considered statistically significant. Studies were repeated 2-3 times.
Results
Experimental design
One day following inoculation of BALB/c mice with 10 5 -10 8 BCL1 leukemia cells (simulating various pre-transplant leukemia loads), each group of mice received one of the 'induction-like' irradiation, and/or cytotoxic-containing conditioning regimens representing BMT induction methods. In several experiments, the mice were followed up for the appearance of leukemia without further manipulation. Due to the apprehension about early toxic death preventing us from analyzing the antileukemic effect, and to evaluate the effect of the induction treatment and the residual disease, AT was performed for untreated BALB/c mice 2-11 days from the conclusion of the treatment ( Figure 1 ). The frame of reference for the various groups was the results of most commonly used myeloablative conditioning regimens, for example high-dose cyclophosphamide and TBI (CY-TBI), 12 or high-dose BU and cyclophosphamide (BU-CY). 13 Thiotepa by itself is not effective against BCL1 leukemia in non-adoptive transfer studies In the first experiment, we explored the effect of two very high TH doses and their antileukemic activity without AT. Mice were inoculated with 10 7 BCL1 cells, then 24 h later Thiotepa and lymphoid malignancies A Abdul-Hai et al treated with either 15 or 25 mg kg À1 of TH, and compared with leukemic control mice (with six mice per group). All groups were monitored on the weekly basis for the appearance of leukemic cells in the peripheral blood, or leukemia-related death. Time to onset of leukemia ranged between 22 and 42 days in the untreated group. Onset of leukemia in animals treated with TH ranged from 20 to 55 and 27 to 49 days in the 15 and 25 mg kg À1 TH dose groups, respectively. Similarly, no difference was noted in the leukemia-related death. Thus, TH alone demonstrated no significant antileukemic activity in the treatment set-up without AT.
Cyclophosphamide-containing regimen is extremely effective against BCL1, whereas thiotepa is not In the second experiment, treatment was started 24 h after inoculation with 10 7 leukemic cells. AT of 10 5 cells was performed 5 and 11 days later. The CY-containing regimens proved to be the most effective ones (Figures 2  and 3 ). CY-TH and BU-CY combinations had similar results. Comparison of the effect of TH-CY treatment versus BU-TH showed only borderline significance (P ¼ 0.067) in favor of TH-CY, when AT was done on day 5. However, the BU-TH combination was found ineffective when AT was performed on day þ 11 (Figure 3 ).
Thiotepa alone does not treat high leukemic load, but produces better synergism than TBI when combined with cyclophosphamide The next step was to evaluate the effect of TH with high tumor load. In this experiment, antileukemic treatment was postponed for 7 days after inoculation with 10 7 spleen BCL1 cells. AT of 10 5 cells was administered 2 and 8 days after treatment with TH, TH-CY or CY-TBI. The results were checked against leukemia control mice that were inoculated with leukemia and received no further treat- Figure 3 Survival of BALB/c mice following inoculation with 10 7 BCL1 followed by treatment with either BU-CY, BU-TH, TH-CY or untreated leukemia control group followed by adoptive transfer on day þ 11. Experiments were repeated twice (n ¼ 8 or 10). BCL1 ¼ B-cell leukemia/ lymphoma; BU-CY ¼ busulfan-cyclophosphamide combination; BU-TH ¼ busulfan-thiotepa combination; TH-CY ¼ thiotepa-cyclophosphamide combination. ment. TH alone had no significant effect as compared to the control group. However, a synergistic effect was seen in the combination of TH-CY: none of the animals developed leukemia, whereas 4/10 animals in the CY-TBI group did (P ¼ 0.029, Figure 4 ).
Thiotepa demonstrates better performance against BCL1 leukemia compared with busulfan and etoposide Inoculation of 10 7 BCL1 was followed by high-dose treatment with TH, BU, BU-CY or TH-CY. AT with 10 6 spleen cells was administered on day þ 7. Results were then compared with the untreated leukemia control group.
BU treatment did not produce a significant effect against BCL1 (all animals developed leukemia after a median of 33 days). Following treatment with TH, in this experiment, 6/9 animals developed leukemia at a median of 41 days (P ¼ 0.003, Figure 5 ). Here, combining CY with either drug was equally effective (0/7 and 0/10 animals developing leukemia in the BU-CY and TH-CY combinations, respectively).
Inoculation with higher doses of BCL1 (10 8 cells) was followed by high-dose treatment with TH, BU, etoposide (VP16), melphalan (MEL) or the TH-VP16, TH-MEL, BU-TH, BU-TH-MEL combinations. AT with 10 5 spleen cells was performed on day þ 6. Results were again compared to the untreated leukemia control group. BU treatment had no significant effect against BCL1 (all animals developed leukemia after a median of 33 days), while following treatment with TH, in this experiment, 6/9 animals developed leukemia at a median of 41 days (P ¼ 0.003, Figure 6 ). Here, combining either drug with CY was equally effective (0/7 and 0/10 animals developing leukemia in the BU-CY and TH-CY groups, respectively).
Interestingly, in this model, the combination of BU with MEL was antagonistic. When administered alone, MEL eradicated BCL1 cells and none of the AT animals developed leukemia. Likewise, when MEL was given in combination with TH, none of the animals developed leukemia. However, the TH-BU-MEL combination TH in multi-drug regimens TH was added to known BMT-conditioning regimens commonly used in human malignant lymphoma. The dosage of the chemotherapeutic agents and the administration schedules were left unchanged. Based on the results presented in Table 2 , we could not identify the role of TH when incorporated with these regimens.
Discussion
Thiotepa is an alkylating agent that reacts with DNA phosphate groups to produce cross-linking of DNA strands leading to inhibition of DNA, RNA and protein synthesis. Although its mechanism of action has not been explored as thoroughly as that of other alkylating agents, it is presumed that the aziridine rings open and react as nitrogen mustard; reactivity is enhanced at a lower pH. Its common side effects include myelosuppression, dizziness, fever, headache and anorexia. Thiotepa is believed to carry a low emetic potential (o10%). It has been used clinically in several conditions, including breast adenocarcinoma, 2 Hodgkin's disease, 5 ovarian adenocarcinoma 14 and transitional cell carcinoma of the bladder. 3, 4 In the context of BMT, TH has been used for multiple myeloma, 6 breast carcinoma, 7 leukemia 8 and lymphoma 9 due to its relative safety and a low-toxicity profile (other than the expected myelosuppression), which render TH preferable over other agents when used in high-dose protocols, without causing further toxicity even in high-risk groups. 6 Yet, the role of TH in combination with other drugs in lymphatic diseases has not been sufficiently studied.
In this report, we present a series of experiments designed to investigate the efficacy of TH and its role in combination with other cytotoxic agents in a murine lymphoid leukemia model. We have found that TH cannot be used as a single agent (even in very high doses-15-25 mg kg
À1
) for treating experimental murine leukemia. However, it was more effective than several drugs commonly used in BMT protocols such as BU and VP-16 ( Figure 5 ), and produced better synergism with CY than TBI (Figure 4) . In our study, only CY and MEL were more effective as single agents within the same experimental framework.
In spite of its disappointing performance as a single agent, TH efficacy was shown when used in conjunction with other agents. A synergistic or additive effect of TH when combined with other agents was established. The combination of TH and CY was as effective as the commonly used BU-CY combination, and more effective than the BU-TH combination. Additionally, we have found that the combination of TH-CY was more effective than CY-TBI. These results are promising since TH may be burdened with fewer short-and long-term side effects than BU (such as generalized or myoclonic seizures, venoocclusive disease (VOD) and a syndrome of diffuse interstitial pulmonary fibrosis, persistent cough, fever, rales and dyspnea also known as 'busulfan lung' 15, 16 ) or TBI (with common side effects such as alterations in pulmonary functions, formation of cataract or sicca syndrome, hypothyroidism and the development of hypogonadism and disturbed growth in children 15, 17 ) thus making TH an excellent candidate for inclusion in pre-BMT myeloablative and non-myeloablative conditioning protocols. Unfortunately, in the experimental set-up of our study and due to the efficacy of other drugs, we have not been able to examine thoroughly the efficacy of TH when incorporated with multi-drug conditioning protocols (Table 2) .
However, one conclusive finding is the following: while combining BU with CY or with TH did not change the conditioning efficacy, the combination of BU and MEL may be antagonistic since the use of MEL alone or in combination with TH prevented totally the development of the experimental leukemia, while with the TH-BU-MEL combination, all animals developed leukemia (Po0.001).
We conclude that TH emerges as a good candidate for pre-stem cell transplantation conditioning regimens in lymphoid malignancies, and ought to be evaluated in allogeneic murine models. This report should be followed with clinical studies; in addition, further evaluation is called for to assess the possible antagonistic interaction between BU and melphalan. 
